HD-OPM Archive
Topics › PCSK9, ezetimibe & newer drugs

Moderate statin plus ezetimibe matched high-intensity statins on MACE with lower LDL

Gokhan Can · Nov 24, 2024 · ♥ 15 reactions · 2 comments · original Facebook post
PCSK9, ezetimibe & newer drugsStatinsLDL, ApoB & lipid panel
AI summary & key facts

Gokhan shares a JAMA Cardiology paper finding that a moderate-intensity statin combined with ezetimibe gives similar major cardiovascular event outcomes to high-intensity statins in ASCVD, while lowering LDL further, with better tolerance and less new diabetes.

A moderate-intensity statin combined with ezetimibe achieves similar MACE outcomes compared to high-intensity statins, while providing superior LDL-c lowering, better tolerance, and a lower incidence of diabetes. https://ja.ma/4fz3eoS (t.co)

Research cited

#statins#ezetimibe#diabetes
← newer: Stanford finds BHB-amino acids, a new keto metabolite familyolder: Review: oleic acid and polyphenols in extra virgin olive oil →